Is spaxentan/sparsentan a new treatment for kidney disease?

Sparsentan/Sparsentan is an innovative non-immunosuppressive single-molecule drug that has emerged in recent years. It is specially designed to treat immunoglobulin A tubulointerstitial disease (IgA nephropathy, referred to as IgAN). IgAN is a specific chronic kidney disease whose core feature is the abnormal deposition of immunoglobulin A in the glomerulus. The cause of this disease is quite complex, not only involving disorders of the immune system, but also being affected by multiple factors such as genetics and environment, which gradually lead to renal function decline.

People with IgAN may experience a range of symptoms including hematuria, proteinuria, high blood pressure, and kidney swelling. If left untreated, kidney function may continue to deteriorate and may eventually evolve into end-stage renal disease, at which time the patient will have to rely on dialysis or receive a kidney transplant. Therefore, early identification and effective treatment of IgAN are crucial. Traditional IgAN therapies mostly rely on immunosuppressants and antihypertensive drugs, but these methods are often accompanied by multiple side effects, and the efficacy varies from person to person, making it challenging.

Sparsentan's unique mechanism is that it can simultaneously inhibit endothelinA receptor (ETAR) and angiotensin II subtype 1 receptor (AT1R). This dual effect significantly reduces inflammatory activity in the glomerulus, reduces the production of proteinuria, and contributes to the recovery and improvement of renal function. Multiple studies have shown that sparsentane can not only significantly reduce the protein content in urine, but also effectively slow the progression of kidney disease. It is particularly worth mentioning that for IgAN patients with hypertension, the therapeutic effect of sparsentane is particularly significant, because hypertension is one of the key factors that aggravates the condition of IgAN.

The innovation of sparsentan lies in its unique dual-targeting mechanism of action, which is unprecedented in the field of IgAN treatment. Compared with traditional single-target drugs, sparsentan shows greater therapeutic potential in controlling the progression of IgAN and delaying its progression through this dual mechanism. In addition, sparsentan has also demonstrated good tolerance and fewer side effects, undoubtedly providing a new treatment strategy for IgAN patients.

References:https://newsroom.csl.com/2024-10-17-CSL-Vifor-and-Travere-Therapeutics-Announce-Swissmedic-approval-of-FILSPARI-R-sparsentan-for-the-treatment-of-IgA-Nephropathy